BMT-124110 manufacturers
- BMT-124110
-
- $329.00
-
2026-07-14
- CAS:1679371-59-5
- Purity: 98.07%
- Supply Ability: 10g
- BMT-124110
-
- $329.00
-
2026-07-14
- CAS:1679371-59-5
- Purity: 98.07%
- Supply Ability: 10g
- BMT-124110
-
- $329.00
-
2025-04-28
- CAS:1679371-59-5
- Purity: 98.93%
- Supply Ability: 10g
|
| | BMT-124110 Basic information |
| Product Name: | BMT-124110 | | Synonyms: | BMT-124110;BMT 124110,BMT124110;Acetamide, N-[8-[[(2S)-2-amino-2,4-dimethylpentyl]oxy]-5H-[1]benzopyrano[3,4-c]pyridin-2-yl]-;BMT-124110, 10 mM in DMSO | | CAS: | 1679371-59-5 | | MF: | C21H27N3O3 | | MW: | 369.46 | | EINECS: | | | Product Categories: | | | Mol File: | 1679371-59-5.mol |  |
| | BMT-124110 Chemical Properties |
| Boiling point | 610.4±55.0 °C(Predicted) | | density | 1.189±0.06 g/cm3(Predicted) | | form | Solid | | pka | 13.36±0.20(Predicted) | | color | White to off-white |
| | BMT-124110 Usage And Synthesis |
| Uses | BMT-124110 is a potent, selective AAK1 inhibitor with an IC50 of 0.9 nM. BMT-124110 shows antinociceptive activity. BMT-090605 inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50s of 17 and 99 nM, respectively[1]. | | in vivo | BMT-124110 is added directly onto the spinal corevd by microiontophoresis, leading to reduction in windup-induced activity in 10 of 14 animals[1]. | | References | [1] Kostich W, et al. Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain. J Pharmacol Exp Ther. 2016 Sep;358(3):371-86. DOI:10.1124/jpet.116.235333 |
| | BMT-124110 Preparation Products And Raw materials |
|